|
|
|
|
|
|
|
|
|
|
|
|
|
Ch. 437 2005 LAWS OF MARYLAND
Disease in Maryland; providing for the membership, chair, and staff for the Task
Force; providing that a member of the Task Force may receive certain
reimbursement as provided in the State budget; providing for the duties of the
Task Force; requiring the Task Force to submit certain reports to the Governor
and the General Assembly on or before certain dates; providing for the
termination of this Act; and generally relating to the Task Force to Study the
Impact of Autoimmune Disease in Maryland.
SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
MARYLAND, That:
(a) There is a Task Force to Study the Impact of Autoimmune Disease in
Maryland.
(b) The Task Force consists of the following members:
(1) one member of the Senate of Maryland, appointed by the President of
the Senate;
(2) one member of the House of Delegates, appointed by the Speaker of
the House;
(3) a representative of the Department of Health and Mental Hygiene,
appointed by the Secretary of Health and Mental Hygiene;
(4) a representative of the Maryland Insurance Administration, selected
by the Administration;
(5) a representative of the Department of Disabilities, appointed by the
Secretary of Disabilities;
(6) a representative of the Vital Statistics Administration, appointed by
the Secretary of Health and Mental Hygiene; and
(7) the following members appointed by the Governor:
(i) one health care provider with special expertise in autoimmune
disease;
(ii) one representative of a health care clinic that serves people with
autoimmune disease;
(iii) one representative from a State hospital that serves people with
autoimmune disease;
(iv) one representative from a State university conducting research
on autoimmune disease;
(v) one representative who is a consumer of autoimmune disease
services and has expertise in autoimmune disease affecting minorities;
(vi) one representative who is a consumer of autoimmune disease
services and has expertise in autoimmune disease affecting women of childbearing
age;
- 2018 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
